Melanoma is remarkably heterogenous. The different subtypes vary in their immunological and clinical profiles, and these differences can have implications for the most appropriate treatment approaches in both advanced disease and adjuvant settings.
In this podcast, medical oncologist at Chris O’Brien Lifehouse Jenny Lee talks to Associate Professor Matteo Carlino, a consultant medical oncologist at Westmead and Blacktown about treatment selection in various histological subtypes of melanoma.
The views expressed in this podcast are the views of the presenters alone and are not necessarily reflective of the views of the sponsor. Please refer to the appropriate product information before prescribing any treatment mentioned in this podcast.
Disclosures
Associate Professor Matteo Carlino has served on advisory boards for Bristol-Myers Squibb, MSD, Amgen, Novartis, Pierre Fabre, Roche, Sanofi, Merck, Ideaya, Regeneron, Nektar, Eisai, Q biotics and honoraria from Bristol-Myers Squibb, MSD, Novartis.
Doctor Jenny Lee has received honorarium (including travel support): BMS, AstraZeneca, Novartis, BioRad.